Skip to content
Clinical Trials – home
Therapeutic area

Eye disorders – page 25

  • 373 clinical trials
  • 123 recruiting
  • 138 conditions
  • 27 countries

Conditions in this area

138 conditions with trials, the busiest first

Clinical trials in Eye disorders

373 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

373 clinical trials

Study on the Safety and Effectiveness of LASN01 for Patients with Thyroid Eye Disease

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:LASN01
  • Sponsor:Lassen Therapeutics 1 Inc.

Uveitis

Not recruiting

Study of Baricitinib and Adalimumab for Children Aged 2 to 17 with Active Juvenile Idiopathic Arthritis-Associated Uveitis or Chronic Anterior Antinuclear Antibody-Positive Uveitis

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Adalimumab
  • Sponsor:Eli Lilly & Co.

Giant cell arteritis

Not recruiting

Comparing Methotrexate and Tocilizumab for Treating Giant Cell Arteritis in Patients: A Study on Effectiveness and Safety

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Folic Acid
  • Sponsor:Centre Hospitalier Universitaire De Dijon

Open angle glaucoma+1

Not recruiting

Study Comparing Brimonidine and Timolol Eye Drops for Patients with Open-Angle Glaucoma or Ocular Hypertension

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Brimonidine Tartrate
  • Sponsor:Becro (Cyprus) Limited

Study on the Safety and Effectiveness of Isocyclosporin A Eye Drops for Adults with Atopic Keratoconjunctivitis

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Fluorescein Sodium
  • Sponsor:Dompe' Farmaceutici S.p.A.

Study on the Effectiveness of Inebilizumab for Patients with IgG4-Related Disease

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Inebilizumab
  • Sponsor:Horizon Therapeutics Ireland Designated Activity Company

Study on the Effectiveness and Safety of Ravulizumab for Children and Adolescents with Neuromyelitis Optica Spectrum Disorder (NMOSD)

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Ravulizumab
  • Sponsor:Alexion Pharmaceuticals Inc.

Study on Patidegib Gel for Reducing Basal Cell Carcinomas in Adults with Gorlin Syndrome

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Patidegib Hydrochloride Isopropanolate
  • Sponsor:Sol-Gel Technologies Ltd.

Dry eye

Not recruiting

Study on the Safety and Effectiveness of Cenegermin Eye Drops for Patients with Dry Eye Disease

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Chloride
  • Sponsor:Dompe' Farmaceutici S.p.A.

Uveitis

Not recruiting

Study on Methotrexate and Adalimumab for Non-Infectious Uveitis in Patients: Evaluating Effectiveness and Safety

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Adalimumab
  • Sponsor:Fundacion Para La Investigacion Biomedica Del Hospital Clinico San Carlos

Study of VRDN-001 for Patients with Thyroid Eye Disease Who Did Not Respond to Previous Treatment

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Sodium Chloride
  • Sponsor:Viridian Therapeutics Inc.

Study on Gene Therapy with VTX-801 and Copper (64Cu) Chloride for Adults with Wilson's Disease

InvestigationalNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years
  • Substances:Adeno-Associated Viral Vector Serotype 3B Encoding Shortened Human Atp7B
  • Sponsor:Vivet Therapeutics

Substances studied in this area

The therapies tested most often in Eye disorders trials.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.